Taro Pharmaceutical Industries Ltd. has received FDA approval for its ANDA for terconazole vaginal cream, 0.4 percent. The generic drug is the bioequivalent to Ortho-McNeil Pharmaceutical's Terazol 7 Vaginal Cream 0.4 percent, an antifungal medication used for the local treatment of vulvovaginal candidiasis, or yeast infections. Terazol had U.S. sales of $42 million for the 12 months ended in September.
COPYRIGHT 2005 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2005 Gale Group